A Phase 3 interventional study of Ibrutinib Oral Capsule and Placebo in Follicular Lymphoma, sponsored by Pharmacyclics LLC.. Completed at 128 sites in 19 countries. Open to participants aged 60 Years and older. Per ClinicalTrials.gov, last updated 2026-03-17.
Sponsored by Pharmacyclics LLC. (part of AbbVie) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 24 studies testing ibrutinib in Lymphoma, Follicular — none open to participants now, 7 under way, 1 of them phase 3. ibrutinib · Lymphoma, Follicular.
Among the 24 studies testing ibrutinib in Lymphoma, Follicular, this one is the 2nd largest by enrollment, is one of 3 that started in 2017, is one of 4 in phase 3, and was the 17th registered.
1,891 studies on the registry are indexed under Lymphoma, Follicular; 289 are open to participants now.
Browse Lymphoma, Follicular studies →None of the 24 studies testing ibrutinib in Lymphoma, Follicular is open now. The open studies under Lymphoma, Follicular, anywhere →
ibrutinib: first FDA approval 2013 (IMBRUVICA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 225 Lymphoma, Follicular studies recruiting now, 158 (70%) set no upper age limit and 39 (17%) stop at 75 or younger; 33 take children under 18; 24 take healthy volunteers.
This study: 60 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
24 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 11 · Phase 3 4
First in 2009; this study’s year is marked. 3 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 445 is above the median of 48 across 1,503 interventional studies indexed under Lymphoma, Follicular.
Median enrollment 48 across the 24 interventional studies. Of the 16 that completed or were terminated, 8 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 24 have an industry lead sponsor. The 10 most frequent:
This study is registered under Pharmacyclics LLC., one of the names counted as AbbVie. Under that name alone:
Pharmacyclics LLC. is the lead sponsor of 54 studies on the registry; none are open to participants now.
Of its 10 completed or terminated interventional studies of FDA-regulated products, 9 (90%) have results posted.
23 studies in Lymphoma, Follicular by AbbVie: 1 open now, 4 under way, none of them phase 3. Of 19 finished, 15 (79%) have results posted.
Among the 23 studies in Lymphoma, Follicular by AbbVie, this one is the 3rd largest by enrollment of the 22 interventional ones that give a count, is the only one that started in 2017, is one of 7 in phase 3, and was the 17th registered.
AbbVie’s Lymphoma, Follicular studies by the year they started, since 2006.
3 of the studies testing ibrutinib in Lymphoma, Follicular that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT01804686Phase 3Janssen Research & Development, LLCA Long-term Extension Study of PCI-32765 (Ibrutinib) | 2026-12-31 |
| NCT01479842Kami Maddocks, MDRituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's Lymphoma | 2026-12-01 |
| NCT04450173University of California, DavisObinutuzumab, Ibrutinib, and Venetoclax for the Treatment of Previously Untreated Stage II-IV Follicular Lymphoma | 2027-04 |
Add all 3 to your calendar (.ics) → With an account.
Among the 24 studies testing ibrutinib in Lymphoma, Follicular, from their registry updates:
Among AbbVie’s 23 in Lymphoma, Follicular:
This tab as a report to print or save as PDF → With an account.
This is a randomized, double-blind, placebo-controlled, multicenter Phase 3 study to evaluate the efficacy and safety of ibrutinib in combination with rituximab versus placebo in combination with rituximab in treatment naïve participants with follicular lymphoma (FL).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants to receive 560mg of ibrutinib once daily and rituximab 375mg/m\^2 weekly x4 with maintenance.
Drug: Ibrutinib Oral Capsule · Drug: Rituximab
Participants to receive placebo once daily and rituximab 375mg/m\^2 weekly x4 with maintenance.
Drug: Placebo · Drug: Rituximab
Ibrutinib 560mg administered orally daily
Also known as: Imbruvica
Placebo capsules to match ibrutinib administered orally daily
Rituximab 375mg/m\^2 intravenously (IV) weekly
Progression-Free Survival (PFS) as Assessed by Investigator
PFS is the time from the date of randomization to the date of the first documented evidence of disease progression (based on the Revised Response Criteria for Malignant Lymphoma \[Cheson 2014, Lugano Classification\]) or death from any cause, whichever occurs first. Participants who initiated subsequent anticancer therapy or missed two or more consecutive overall disease assessments were censored as described in the SAP. Estimated by Kaplan-Meier method.
Time frame: Primary Analysis cut-off; median overall follow-up of 53.75 months
Overall Response Rate (ORR) as Assessed by Investigator
ORR is the proportion of participants who achieved a best overall response of complete response (CR) or partial response (PR) as determined by the investigator according to the Revised Response Criteria for Malignant Lymphoma (Cheson 2014, Lugano Classification). ORR was assessed from the date of randomization through the date of first documented disease progression or initiation of subsequent anti-cancer therapy, whichever occurred first. Participants who did not have any post-baseline disease assessments or who initiated subsequent anti-cancer therapy prior to a documented response are considered non-responders.
Time frame: Primary Analysis; median overall follow-up of 53.75 months
Overall Survival (OS)
Overall survival is defined as the interval between the date of randomization and the date of the participant's death from any cause. If a participant is not known to have died (this includes participants with unknown death date), OS will be censored at the date the participant was last known to have been alive. Estimated by Kaplan-Meier method.
Time frame: Final Analysis; median overall follow-up of 58.97 months
Infusion-related Reaction Rate Assessed by Investigator
The infusion-related reactions (IRR) rate is the proportion of subjects experiencing infusion related reactions that start on the day of a rituximab infusion and are assessed as related or possibly related to rituximab.
Time frame: Primary Analysis; median overall follow-up of 53.75 months
Duration of Response (DOR) as Assessed by Investigator
DOR is defined as the time from initial complete response (CR) or partial response (PR) to progressive disease (PD) or death due to any cause, whichever is first reported, regardless of discontinuation of study treatment. If such event did not occur, then participants were to be censored at the last adequate disease assessment as required for PFS censoring. Estimated by Kaplan-Meier method.
Time frame: Primary Analysis; median overall follow-up of 53.75 months
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
An AE is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. The treatment-emergent period is defined as the period from the date of the first dose of study treatment up to 30 days after the date of the last dose of study treatment or the day before initiation of subsequent anti-cancer therapy, whichever comes first. The treatment-emergent adverse events (TEAEs) are those events that occur or worsen during the treatment-emergent period or that are related to the study treatment.
Time frame: Overall median treatment duration of 22.11 months
In total, 445 participants were enrolled at 128 sites in 19 countries. Participants were randomly assigned in a 3:1 ratio to the Ibrutinib + Rituximab arm (Arm A; n=334) or the Placebo + Rituximab arm (Arm B; n=111). Randomization was stratified on the basis of: (a) age (60-69 vs. ≥70 years), (b) Follicular Lymphoma-specific International Prognostic Index (FLIPI)-1 score (low vs. intermediate/high) and (c) ECOG performance status score (0/1 vs. 2).
| Milestone | Arm A: Ibrutinib + Rituximab | Arm B: Placebo + Rituximab |
|---|---|---|
| Started | 334 | 111 |
| On study treatment at study closure | 50 | 22 |
| Off treatment and on follow-up at study closure | 108 | 33 |
| Completed | 158 | 55 |
| Not completed | 176 | 56 |
| Withdrew: Death | 109 | 35 |
| Withdrew: Lost to follow-up | 7 | 4 |
| Withdrew: Withdrawal of consent | 50 | 14 |
| Withdrew: Other | 10 | 3 |
PFS is the time from the date of randomization to the date of the first documented evidence of disease progression (based on the Revised Response Criteria for Malignant Lymphoma \[Cheson 2014, Lugano Classification\]) or death from any cause, whichever occurs first. Participants who initiated subsequent anticancer therapy or missed two or more consecutive overall disease assessments were censored as described in the SAP. Estimated by Kaplan-Meier method.
| months | Arm A: Ibrutinib + Rituximab | Arm B: Placebo + Rituximab |
|---|---|---|
| Progression-Free Survival (PFS) as Assessed by Investigator | 42.02 (33.31 to 50.83) | 32.76 (22.05 to 38.67) |
ORR is the proportion of participants who achieved a best overall response of complete response (CR) or partial response (PR) as determined by the investigator according to the Revised Response Criteria for Malignant Lymphoma (Cheson 2014, Lugano Classification). ORR was assessed from the date of randomization through the date of first documented disease progression or initiation of subsequent anti-cancer therapy, whichever occurred first. Participants who did not have any post-baseline disease assessments or who initiated subsequent anti-cancer therapy prior to a documented response are considered non-responders.
| percentage of participants | Arm A: Ibrutinib + Rituximab | Arm B: Placebo + Rituximab |
|---|---|---|
| Overall Response Rate (ORR) as Assessed by Investigator | 81.4 (76.8 to 85.5) | 68.5 (59.0 to 77.0) |
Overall survival is defined as the interval between the date of randomization and the date of the participant's death from any cause. If a participant is not known to have died (this includes participants with unknown death date), OS will be censored at the date the participant was last known to have been alive. Estimated by Kaplan-Meier method.
| months | Arm A: Ibrutinib + Rituximab | Arm B: Placebo + Rituximab |
|---|---|---|
| Overall Survival (OS) | NA (69.72 to NA) | 78.98 (57.36 to NA) |
The infusion-related reactions (IRR) rate is the proportion of subjects experiencing infusion related reactions that start on the day of a rituximab infusion and are assessed as related or possibly related to rituximab.
| percentage of participants | Arm A: Ibrutinib + Rituximab | Arm B: Placebo + Rituximab |
|---|---|---|
| Infusion-related Reaction Rate Assessed by Investigator | 21.3 (17.0 to 26.0) | 27.0 (19.0 to 36.3) |
DOR is defined as the time from initial complete response (CR) or partial response (PR) to progressive disease (PD) or death due to any cause, whichever is first reported, regardless of discontinuation of study treatment. If such event did not occur, then participants were to be censored at the last adequate disease assessment as required for PFS censoring. Estimated by Kaplan-Meier method.
| months | Arm A: Ibrutinib + Rituximab | Arm B: Placebo + Rituximab |
|---|---|---|
| Duration of Response (DOR) as Assessed by Investigator | 44.25 (36.63 to NA) | 34.56 (29.21 to 47.31) |
An AE is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. The treatment-emergent period is defined as the period from the date of the first dose of study treatment up to 30 days after the date of the last dose of study treatment or the day before initiation of subsequent anti-cancer therapy, whichever comes first. The treatment-emergent adverse events (TEAEs) are those events that occur or worsen during the treatment-emergent period or that are related to the study treatment.
| Participants | Arm A: Ibrutinib + Rituximab | Arm B: Placebo + Rituximab |
|---|---|---|
| Any Treatment-Emergent Adverse Event (TEAE) | 324 | 106 |
| Grade ≥3 TEAEs | 259 | 63 |
| Serious Adverse Events (SAEs) | 204 | 45 |
| Fatal TEAEs | 48 | 6 |
| Discontinued study drug due to AE | 144 | 16 |
| Most frequent Grade ≥3 TEAE (neutropenia) | 52 | 8 |
Collected over All-cause mortality and adverse event tables include events reported from the time of informed consent/enrollment to the end of the study. The median time on follow-up (or mean time participants were followed) was 58.2 months for Arm A (Ibrutinib + Rituximab) and 60.0 months for Arm B (Placebo + Rituximab).. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Arm A: Ibrutinib + Rituximab | 123/334 (36.8%) | 214/334 (64.1%) | 310/334 (92.8%) |
| Arm B: Placebo + Rituximab | 40/111 (36%) | 48/111 (43.2%) | 101/111 (91%) |
| Event | Arm A: Ibrutinib + Rituximab | Arm B: Placebo + Rituximab |
|---|---|---|
| PNEUMONIAInfections and infestations | 36/334 | 5/111 |
| COVID-19Infections and infestations | 25/334 | 1/111 |
| ATRIAL FIBRILLATIONCardiac disorders | 21/334 | 2/111 |
| COVID-19 PNEUMONIAInfections and infestations | 21/334 | 5/111 |
| URINARY TRACT INFECTIONInfections and infestations | 11/334 | 4/111 |
| PLEURAL EFFUSIONRespiratory, thoracic and mediastinal disorders | 5/334 | 3/111 |
| DEATHGeneral disorders | 2/334 | 2/111 |
| GASTROENTERITISInfections and infestations | 1/334 | 2/111 |
| INFLUENZAInfections and infestations | 3/334 | 2/111 |
| HUMERUS FRACTUREInjury, poisoning and procedural complications | 0/334 | 2/111 |
| Event | Arm A: Ibrutinib + Rituximab | Arm B: Placebo + Rituximab |
|---|---|---|
| DIARRHOEAGastrointestinal disorders | 116/334 | 15/111 |
| FATIGUEGeneral disorders | 72/334 | 16/111 |
| NAUSEAGastrointestinal disorders | 69/334 | 12/111 |
| NEUTROPENIABlood and lymphatic system disorders | 67/334 | 12/111 |
| COVID-19Infections and infestations | 62/334 | 22/111 |
| OEDEMA PERIPHERALGeneral disorders | 63/334 | 18/111 |
| ARTHRALGIAMusculoskeletal and connective tissue disorders | 63/334 | 16/111 |
| DYSPNOEARespiratory, thoracic and mediastinal disorders | 38/334 | 20/111 |
| DRY EYEEye disorders | 60/334 | 17/111 |
| URINARY TRACT INFECTIONInfections and infestations | 60/334 | 10/111 |
ITT Population
| Age, Continuous(Years) | Arm A: Ibrutinib + Rituximab | Arm B: Placebo + Rituximab | Total |
|---|---|---|---|
| Mean | 73.7 ± 6.38 | 74.2 ± 5.96 | 73.8 ± 6.28 |
| Sex: Female, Male(Participants) | Arm A: Ibrutinib + Rituximab | Arm B: Placebo + Rituximab | Total |
|---|---|---|---|
| Female | 183 | 53 | 236 |
| Male | 151 | 58 | 209 |
| Ethnicity (NIH/OMB)(Participants) | Arm A: Ibrutinib + Rituximab | Arm B: Placebo + Rituximab | Total |
|---|---|---|---|
| Hispanic or Latino | 19 | 8 | 27 |
| Not Hispanic or Latino | 304 | 103 | 407 |
| Unknown or Not Reported | 11 | 0 | 11 |
| Race (NIH/OMB)(Participants) | Arm A: Ibrutinib + Rituximab | Arm B: Placebo + Rituximab | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 1 | 1 |
| Asian | 13 | 10 | 23 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 2 | 0 | 2 |
| White | 304 | 97 | 401 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 15 | 3 | 18 |
Showing the first 100 of 128 sites across 19 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jan 2017 to primary completion in Feb 2024, 84 months.
Results were first posted in Mar 2026, 2 years after primary completion. A results delay was requested in Jan 2025.
Of 45 industry-sponsored phase 3 interventional studies under Lymphoma, Follicular, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 86. This study's 84 months is above that.
Counting every sponsor, half of 80 studies reached it within 63 months; a quarter within 36 and three quarters within 106.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ibrutinib